Bock Joshua M, Johnson Stephen, Kashyap Purna C, Somers Virend K, Cheung Joseph
Department of Cardiovascular Medicine, Mayo Clinic, 200 First St. SW Rochester, MN, 55905, United States.
Department of Quantitative Health Sciences, Mayo Clinic, 200 First St. SW Rochester, MN, 55905, United States.
Sleep Med. 2024 Jun;118:39-42. doi: 10.1016/j.sleep.2024.03.042. Epub 2024 Apr 4.
OBJECTIVE/BACKGROUND: Microbes within the gastrointestinal tract have emerged as modulators of the host's health. Obstructive sleep apnea (OSA) is characterized by intermittent partial, or complete, airway closure during sleep and is associated with increased risk of non-communicable diseases as well as dysbiosis of the gut microbiome. Thus, we investigated if improving nocturnal airway patency via positive airway pressure (PAP) therapy improves gut microbial diversity in recently diagnosed patients with moderate-to-severe OSA (apnea-hypopnea index ≥15.0 events/hr).
PATIENTS/METHODS: Eight subjects (3 F, 56±9yrs, 33.5 ± 7.7 kg/m, 45.0 ± 38.4 events/hr) provided stool samples before, and two months after, PAP therapy (mean adherence of 95 ± 6%, residual apnea-hypopnea index of 4.7 ± 4.6 events/hr).
While the Shannon diversity index tended to increase following PAP (3.96 ± 0.52 to 4.18 ± 0.56, p = 0.08), there were no changes in the Observed (1,088 ± 237 to 1,136 ± 289, p = 0.28) nor Inverse-Simpson (22.4 ± 12.99 to 26.6 ± 18.23, p = 0.28) alpha diversity indices. There were also no changes in beta diversity assessed using the Bray-Curtis (p = 0.98), Jaccard (p = 0.99), WUniFrac (p = 0.98), GUniFrac (p = 0.98), or UniFrac (p = 0.98) methods. No changes in differential abundance taxa were found using a false discovery rate threshold of <0.20.
Our data are the first to report that PAP therapy may not offset, or reverse, gut dysbiosis in patients with OSA. Accordingly, interventions which improve gut microbial health should be explored as potential adjunctive treatment options in patients with OSA to reduce their risk of developing non-communicable diseases.
目的/背景:胃肠道内的微生物已成为宿主健康的调节因子。阻塞性睡眠呼吸暂停(OSA)的特征是睡眠期间间歇性部分或完全气道关闭,并与非传染性疾病风险增加以及肠道微生物群失调有关。因此,我们研究了通过气道正压通气(PAP)治疗改善夜间气道通畅性是否能改善近期诊断为中度至重度OSA(呼吸暂停低通气指数≥15.0次/小时)患者的肠道微生物多样性。
患者/方法:8名受试者(3名女性,56±9岁,体重指数33.5±7.7kg/m²,呼吸暂停低通气指数45.0±38.4次/小时)在PAP治疗前及治疗后两个月提供粪便样本(平均依从性95±6%,残余呼吸暂停低通气指数4.7±4.6次/小时)。
虽然PAP治疗后香农多样性指数有增加趋势(从3.96±0.52增至4.18±0.56,p=0.08),但观察到的物种数(从1088±237增至1136±289,p=0.28)和逆辛普森指数(从22.4±12.99增至26.6±18.23,p=0.28)的α多样性指数均无变化。使用布雷-柯蒂斯法(p=0.98)、贾卡德法(p=0.99)、加权非加权 UniFrac 法(p=0.98)、非加权 UniFrac 法(p=0.98)或 UniFrac 法(p=0.98)评估的β多样性也无变化。使用错误发现率阈值<0.20未发现差异丰度分类群有变化。
我们的数据首次表明,PAP治疗可能无法抵消或逆转OSA患者的肠道菌群失调。因此,应探索改善肠道微生物健康的干预措施,作为OSA患者潜在的辅助治疗选择,以降低其患非传染性疾病的风险。